OBGYN & Reproduction Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of OBGYN & Reproduction Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study of 4-hydroxytamoxifen gel published in Journal of Clinical Oncology
July 4th, 2005
Ascend Therapeutics, a researcher and developer of pharmaceutical transdermal therapies for treating chronic conditions, announced that researchers have published findings about the company's investigational drug 4-hydroxytamoxifen (4-OHT) gel in the May 2005 issue of the Journal of Clinical Oncology. The study, "Neoadjuvant Percutaneous 4-Hydroxytamoxifen Decreases Breast Tumoral Cell Proliferation: A Prospective Controlled Randomized Study Comparing 3 Doses of 4-Hydroxytamoxifen Gel to Oral Tamoxifen," was led by Dr. Philippe Rouanet of the Centre Val d'Aurelle in Montpellier, France. Results of the published study suggest that 4-OHT gel...
Source: OBGYN & Reproduction Week (2005-07-04)
|
